A Phase 2 Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor) MLN0128+MLN1117 (a PI3Ka Inhibitor) Weekly Paclitaxel or the Combination of Weekly Paclitaxel and MLN0128 in women With Advanced Recurrent or Persistent Endometrial Cancer (C31004)